Skip to NavigationSkip to content

Pharmafile - Research and Development News

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating the...
From narrow trial misses to dire Brexit health forecasts, check out the top ten most popular articles on Pharmafile.com this week!
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and commercialise the...
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment...
The number of cancer drug approvals in the US has surged over the last decade to account for over one in four of all therapy authorisations from...
Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends in engagement...
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the tyrosine kinase...
Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at...
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS in England and Wales...
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches